Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
... As Suppliers Shift Offerings
by Ann M. Thayer
December 8, 2008
| A version of this story appeared in
Volume 86, Issue 49
Introgen Therapeutics is reorganizing to focus on its Houston-based manufacturing and service business, Introgen Technical Services. The firm has declared bankruptcy and will cut about 30 of its 45 employees. A few employees will continue to support regulatory filings for the company's anticancer therapy Advexin. Meanwhile, in the face of lower demand from small biotech firms, Wuxi PharmaTech says it will cease biologics manufacturing at its Philadelphia site, eliminating about 100 jobs, and instead devote the facility to biologics testing and cell services.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X